IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial

IMUNON, Inc. (NASDAQ: IMNN) provided an update on its IMNN-001 development program for advanced ovarian cancer during its 2026 R&D Day. The presentation included final overall survival results from the Phase 2 OVATION 2 Study and preliminary findings from a minimal residual disease study conducted with Break Through Cancer. Additionally, the company highlighted progress in the ongoing Phase 3 OVATION 3 trial, which aims to confirm these findings.